Aceragen | IDRA - Прибыль до налогообложения



Прибыль до налогообложения Изменить Дата
Abbott USD 2.39B 27M 2026-03
Agenus USD -10.61M 263.52M 2025-12
Alnylam Pharmaceuticals USD 221.65M 60.52M 2026-03
Alterity Therapeutics Limited AUD -4.74M 3.53M 2024-12
Amgen USD 1.51B 2.41B 2025-12
Biogen USD 377.7M 433.7M 2026-03
BioMarin Pharmaceutical USD 141.2M 168.36M 2026-03
Cipla INR 7.49B 4.2B 2026-03
Clal Biotechnology ILS 86.82M 17.9M 2022-12
Compugen USD 56.84M 63.78M 2025-12
CSL USD 2.61B 1.21B 2025-12
Eli Lilly USD 8.27B 1.03B 2025-12
Gilead Sciences USD 2.08B 1.56B 2025-12
GlaxoSmithKline GBP 2.14B 919M 2026-03
Grifols EUR 257.85M 190.87M 2024-12
Merck USD 3.42B 3.32B 2025-12
Nektar Therapeutics USD -34.7M 2.35M 2025-12
Pfizer USD 5.18B 6.82B 2026-03
Roche Holding CHF 4.79B 3.01B 2025-06
Sarepta Therapeutics USD 343.17M 750.85M 2026-03
Ultragenyx Pharmaceutical USD -184M 56M 2026-03
X T L Biopharmaceuticals USD -385K 168K 2024-12